Omaveloxolone - Reata Pharmaceuticals

Drug Profile

Omaveloxolone - Reata Pharmaceuticals

Alternative Names: ABT-RTA-408; RTA-408

Latest Information Update: 26 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer AbbVie; Friedreichs Ataxia Research Alliance; Reata Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Small molecules; Triterpenes
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Friedreich's ataxia; Mitochondrial disorders; Ocular inflammation; Ocular pain
  • Phase I/II Malignant melanoma
  • Phase I Non-small cell lung cancer
  • Discontinued Duchenne muscular dystrophy; Radiation-induced skin damage

Most Recent Events

  • 20 Jul 2018 Omaveloxolone is available on a Expanded Access Programme for the treatment of Malignant melanoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (NCT03593499)
  • 10 Jul 2018 Omaveloxolone - Reata Pharmaceuticals receives Orphan Drug status for Friedreich's ataxia in European Union
  • 25 Apr 2018 Pharmacodynamics data from preclinical studies in Friedreich’s ataxia and neurological diseases presented at the 70th Annual Meeting of American Academy of Neurology Annual Meeting (AAN-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top